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Abstract
Background: Fenofibrate, a PPAR alpha agonist, has been widely used in clinics as lipid-regulating agent. PPAR
alpha is known to be expressed in many organs including pancreatic beta cells and regulate genes involved in
fatty acid metabolism. Some reports based on cell lines or animals have provided evidences that PPAR alpha
agonists may affect (increased or suppressed) beta cell insulin secretion, and several studies are producing
interesting but still debated results.
Methods: In this research, we investigated the long term effects of fenofibrate on beta cell function in a metabolic
syndrome animal model, monosodium glutamate (MSG) induced obese rats. Obese MSG rats were administered by
gavage with fenofibrate at a dose of 100 mg/kg for 12 weeks. Oral glucose tolerance and insulin tolerance tests
were performed to evaluate glucose metabolism and insulin sensitivity. We have used the hyperglycemic clamp
technique to evaluate the capacity of beta cell insulin secretion. This technique provides an unbiased approach to
understand the beta cell function in vivo. The changes of gene and protein expression in the pancreas and islets
were also analyzed by Real-Time-PCR, Western blot and immunostaining.
Results: Fenofibrate reduced the plasma lipid levels within a few days, and showed no beneficial effects on glucose
homeostasis or insulin sensitivity in obese MSG rats. But the animals treated with fenofibrate exhibited significantly
decreased fasting plasma insulin and impaired insulin secretory response to glucose stimulation. Further studies confirmed
that fenofibrate increased MDA level and decreased total ATPase activity in pancreatic mitochondrion, accompanied by
the upregulation of iNOS and NF-kappa B and TNF alpha expression in pancreatic islets of obese MSG rats.
Conclusions: Long-term fenofibrate treatment disrupted beta cell function, and impaired glucose-stimulated insulin
secretion in obese MSG rats, perhaps to some extent associated with the activated inflammatory pathway and
increased formation of oxidative products, especially the up-regulation of NF-kappa B and iNOS expression in islets.
Background
Peroxisome proliferator-activated receptor alpha is an
important mediator of fatty acids metabolism by regulat-
ing the expression of genes involved in lipid metabolism
[1]. Many reports suggested that PPAR alpha activation
could improve the peripheral insulin resistance by
relieving lipid-mediated inhibition of insulin-stimulated
glucose disposal in both rodents and humans [2,3].
Furthermore, PPAR alpha is also known to be expressed
in islets. Many studies have indicated that some PPAR
alpha agonists (the class of Fibrates) may affect insulin
secretion in vitro [4]. Some evidences showed that
PPAR alpha activation improved insulin secretion at low
glucose concentrations in isolated rat pancreatic islets
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any medium, provided the original work is properly cited.[5-9]. While PPAR alpha overexpression also stimulated
fatty acid oxidation and impaired beta cell function
independent of triglyceride content in insulinoma cells
[10]. In some extent, such results of PPAR alpha agonist
on insulin secretion showed a certain contradictory.
In order to confirm the direct effect of a PPAR alpha
agonist, fenofibrate, on beta cell function in vivo,w e
chose obese MSG rats to identify insulin secretion after
long-term fenofibrate treatment. The monosodium glu-
tamate (MSG) neonatal administration after birth in
mice or rats provides a model of obesity, which have
been used as an metabolic dysfunction animal model
and exhibited impaired glucose tolerance and insulin
resistance for about 4-6 months old [11,12].
Our primary work has shown that fenofibrate treat-
ment significantly decreased fasting plasma insulin in
obese MSG rats without improving insulin sensitivity,
we hypothesize that fenofibrate may cause an adverse
effect on insulin secretion in this model.
Recently, it was emphasized that PPAR alpha has both
direct effects on the islet itself and indirect effects via mod-
ulation of the mediators involved in insulin secretion and
systemic inflammatory. Besides, beta cells were known to
be particularly susceptible to reactive oxygen species
damage since they have relatively low expression of antioxi-
dant enzymes [13-15]. The augmented reactive oxygen or
nitrogen species (ROS/RNS) generation may play an
important role in the diminished activity of beta cells.
Therefore, we observed the circulating and pancreatic
SOD, MDA, NO content to confirm the effect of fenofi-
brate on ROS/RNS. The metabolic factors invovled in insu-
lin secretion process, including intracellular ion transport,
mitochondrial ATP production, are discussed. ATPase is
involved in maintaining ions gradients across the beta cell
plasma membrane, and is thought to modulate the ATP
level for the maintenance of homeostasis [16,17]. In addi-
tion, several pancreatic protein and enzymes, which were
involved in insulin biosynthesis, exocytosis, energy metabo-
lism and inflammatory pathway, were also associated with
beta cells insulin secretory function.
Methods
Animals
Wistar rats were purchased from the Institute of
Laboratory Animal Science, CAMS & PUMC. Monoso-
dium glutamate (MSG) at a dose of 4 g/kg body weight
was subcutaneously injected to neonatal Wistar rats
once daily for 7 consecutive days after birth to induce
obese rat model. Compared to the normal rats, fasting
plasma concentrations of triglyceride and insulin were
significantly elevated in obese MSG rats at the age of
about six months. At this time, the animals exhibited
obvious features of insulin resistance and visceral obe-
sity, and could be considered as a typical metabolic
syndrome animal model. There are three experiment
groups in this study: Normal rats group (Nor), obese
MSG rats control group (Con), obese MSG rats treated
with fenofibrate group (Fen). 6 months old obese MSG
rats with insulin resistance (Male, average body weight
775 g) were selected and divided into two groups (n =
12/group) as Con and Fen: Con group was orally admi-
nistered by gavage with water and Fen group with feno-
fibrate (Beijing Yimin pharmaceutical Co. 100 mg
fenofibrate/tablet) at a dose of 100 mg/kg per day for
about 12 weeks. Ten fenofibrate tablets were ground
and dissolved into 50 ml water to prepare suspension
for gavaging 0.5 ml/100 g body weight every day. Age
matched normal rats (Male, average body weight 529 g,
n=1 2 )w e r eu s e da sN o rg r o u pt r e a t e dw i t hw a t e r .
Throughout the 12-weeks administration period, body
weight, water and food intake were recorded weekly.
Four hours fasting glycaemia and lipid levels were mea-
sured fortnightly and plasma insulin concentrations
were measured at days 18, 40 and in clamp test. Oral
glucose tolerance tests (OGTTs) were conducted on day
14, 28 and 41, insulin tolerance tests (ITT) on day 25
and 56. After 12 weeks treatment, six animals from each
group were evaluated the beta cell function by hypergly-
cemic clamp. The remaining animals were euthanized
for plasma biochemical indices assay and the pancreas
was excised for determination of some pancreatic speci-
fic mRNA and protein levels. All animals were housed
in an air-conditioned room with a constant 12 h light/
dark cycle at 23 ± 2°C., and had free access to water
and standard chow. All animals were handled in accor-
dance with The Standards for Laboratory Animals
(GB14925-2001) and The Guideline on the Humane
Treatment of Laboratory Animals (MOST 2006a) estab-
lished by the People’s Republic of China. The two guide-
lines were conducted in adherence to the regulations of
Institutional Animal Care and Use Committee (IACUC)
and all animal protocols were approved by IACUC.
Oral glucose tolerance test (OGTT) and insulin tolerance
test (ITT)
Rats were fasted for 4 h and blood was sampled from
tail for glucose assay by the glucose oxidase method at
baseline (as 0 min) and 30, 60 and 120 min after glucose
(2 g/kg) loading in OGTT or 40 and 90 min after insu-
lin (0.4 IU/kg) subcutaneous injection in ITT.
Hyperglycemic clamp
The clamp was performed on 12th week after treatment.
On the tested day, the animals were fasted for 10 h and
then anesthetized with pentobarbital sodium (50 mg/kg
body weight, intraperitoneally) and placed on a heating
pad at 37°C. The anesthetics were reinforced every 60
min. The right jugular vein was catheterized (Micro-
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and the right femoral artery for the sampling. After
operation, the animal rested for 30 min to lessen the sti-
mulation. Then D-glucose was rapidly injected at a dose
of 0.25 g/kg body weight in 1 min, followed a continu-
ous infusion of glucose (50%) at a rate of 10-20 μl/min
[18,19]. Blood samples were collected initially (0 min)
and then every 5 or 10 min throughout the test. Plasma
glucose concentration was monitored instantaneously to
adjust the infusion rate of glucose and keep a hypergly-
cemia nearly 14 ± 0.5 mmol/l. Blood samples of 100 μl
were taken in heparinized tubes at 0, 5, 10 min and the
plasma was stored at -20°C for insulin analysis.
Preparation of pancreas and pancreatic mitochondria
Half of the animals were euthanized after twelve weeks-
treatment. The pancreas was immediately excised,
rinsed, blotted, and weighed. Then the pancreas was cut
into four fractions. One fraction was fixed in 4% paraf-
ormaldehyde for immunofluorescence analysis and the
left were stored at -80°C for further analysis. Pancreatic
tissue samples (100 mg) were homogenized in ice-cold
buffer (10 mM TRIS-HCl, pH7.5, 1 mM EDTA, 250
mM sucrose). After the centrifugation, the supernatant
was collected for assessment of lipid level and inflamma-
tory products in the pancreas.
Biochemical analysis
Plasma glucose was measured by the glucose oxidase
method, and plasma levels of triglycerides (TG), total cho-
lesterol (TC), high density lipoprotein-cholesterol (HDL-C),
low density lipoprotein-cholesterol (LDL-C), Malondialde-
hyde (MDA), superoxide dismutase (SOD), nitric oxide
(NO) and pancreatic mitochondrial ATPase activity were
determined by enzymatic colorimetric methods with com-
mercial kits (BioSino Inc.). Plasma insulin was measured by
radioimmunoassay kit (Beijing Northern Bio. Inc.). Protein
content was assayed according to the method of Lowry,
using bovine serum albumin (BSA) as standard [20].
Real Time PCR
Total RNA was extracted from pancreatic tissues from
each group (4-6 animals) using TRIzol (Invitrogen). Total
RNA (2 μg) was used for reverse transcription (RT) to
synthesize complementary DNA with M-MLV reverse
transcriptase, and real-time fluorescent detection PCR
analysis was performed using Sybr-Green Dye PCR Master
Mix (Takara Biotechnology Co. Ltd.) according to ABI
7000 PCR instrument recommendations (Applied Biosys-
tems Japan Ltd., Tokyo, Japan). The theoretical basis for
quantitation using real-time PCR has been described else-
where [21]. Quantitative Real-time PCR analysis was car-
ried out with the following cycle profile: 1 cycle at 95°C
for 30 s, and 40 cycles at 95°C for 5 s, 60°C for 31 s.
Primers sequences were as follows: iNOS 5’-CTG
AAGCACTAGCCAGGGAC-3’ and 5’-CAAATGTGC
TTGTCACCACC-3’; NF-kappa B 5’-ACAGTAGA-
GAAGTTGTATGCAGC-3’ and 5’-GTGAGGTAGGTA
TCTGAGGCA-3’; PPARalpha 5’-AGAGCCCCATCTG
TCCTCTC-3’ and 5’-ACTGGTAGTCTGCAAAAC-
CAAA-3’; UCP2 5’-ACTTTCCCTCTGGATACCGC-3’
and 5’-ACGGAGGCAAAGCTCATCTG-3’.
Immunofluorescence
Paraffin-embedded pancreas tissues were cut into 2 μm
sections and dewaxed using xylene, rehydrated through
serial dilutions of ethyl alcohol [22]. The sections were
washed and incubated with the antibodies diluted in 150
mM NaCl, 0.05% Tween-20, and 10 mM Tris-HCL
(pH7.4). Primary antibodies used were mouse anti-insu-
lin and rabbit polyclonal NOS2 antibody (diluted 1:50;
Santa Cruz Biotechnology). Secondary antibodies used
were FITC-conjugated goat anti-rabbit IgG and TRITC-
conjugated goat anti-mouse IgG (Beijing zhongshanjin-
qiao Co.). Imaging was performed using a Leica TCS
SP2 laser scanning confocal microscope (Nikon), and
images were analyzed by the Image pro plus software.
Western blot
Tissue samples were homogenized in lysis buffer (50 mM
TRIS-HCl, 2% SDS, 10% glycerol) supplemented with pro-
tease inhibitor cocktail (P1265, Applygen Inc.). The homo-
genate was centrifuged at 12000 g for 10 min and the
supernatant was taken to determine the protein concentra-
tions. The soluble proteins were quantitated following the
Lowry method. Equal amount of samples were resolved
electrophoretically on a 10% sodium dodecyl polyacryla-
mide gel and transferred to polyvinylidene difluoride mem-
branes. The membranes were probed using standard
procedures and the signal was visualized by using an
enhanced chemiluminescence detection system (Chemi-
Scope2850, CLiNX science Instruments). Protein band den-
sities were analyzed using Gel-Pro-Analyzer 3.1 software.
Statistical analysis
Data were expressed as the mean ± standard error of
the mean (SEM). The data obtained in the present study
were analyzed using an ANOVA. A p value < 0.05 was
considered to be statistically significant.
Results
Fenofibrate showed no improvement in glucose homeostasis
but decreased plasma insulin level in obese MSG rats
The fasting blood glucose level was slightly higher (p
<0.05) in fenofibrate treated group, compared to control
group. Additionally, plasma glucose level at 120 min in
OGTT was higher in fenofibrate treated group than
control group (p <0.01, Figure 1A). However, AUC in
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Page 3 of 11Figure 1 Fenofibrate showed no improvement in glucose homeostasis but decreased plasma insulin level in obese MSG rats. (A) Blood
glucose level during the OGTT. (B) Increased percentage of blood glucose at each time point in OGTT. (C) Blood glucose level during the ITT. (D)
Decreased percentage of glucose level at each time point in ITT. OGTT was performed in 4 h fasted animals on 6th week of treatment and ITT
on 7th week. (E) Plasma superoxide dismutase level, (F) Plasma malondialdehyde level, (G) Plasma nitric oxide level, and (H) Plasma insulin level
in obese MSG rats treated with water or fenofibrate. Nor, normal rats. Con, water treated obese MSG rats. Fen, fenofibrate treated obese MSG
rats. Values represented means ± s.e.m. (n = 10-12). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
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between fenofibrate treated group and control group
(Figure 1B and 1D).
Some representative indices of anti-oxidative system
were investigated during the administration. Plasma
SOD level in obese MSG rats was lower than in normal
group (194.4 ± 6.6 versus 214.6 ± 4.2 IU/ml, p <0.05).
Fenofibrate treatment failed to improve plasma SOD
level (Figure 1E), and resulted in distinguished augmen-
tation in plasma MDA content, a typical oxidative stress
marker (11.4 ± 0.4 versus 9 . 5±0 . 5n m o l / m l ,p< 0 . 0 5 ,
Figure 1F). Meanwhile, plasma NO was significantly
54.5 percent higher in fenofibrate group than in control
group (118.2 ± 10.8 versus 76.4 ± 7.1 μmol/l, p <0.01,
Figure 1G). Fasting plasma insulin level was elevated in
obese MSG rats with insulin resistance. Interestingly,
although failed to improve insulin tolerance, fenofibrate
treatment led to the decrease of plasma insulin level by
43.3% compared to control group (2.1 ± 0.7 versus 3.7 ±
1.4 ng/ml, p <0.01, Figure 1H).
Fenofibrate alleviates dyslipidemia in obese MSG rats
Obese MSG rats developed hypercholesterolaemia and
hypertriglyceridaemia with increased plasma TG and
TC levels (Figure 2A and 2B), and higher plasma
LDL-C fractions (Figure 2D) compared to normal
group. Notably, fenofibrate treatment could alleviate
the dyslipidemia, leading to 52% reduction in plasma
cholesterol level and 45% reduction in triglyceride
level, as well as reduced LDL-C and HDL-C levels
(Figure 2).
Fenofibrate affects insulin secretion in obese MSG rats
Next we performed hyperglycemic clamp experiments
to evaluate beta cell function. A rapid rise in plasma
glucose level appeared within 5 min in the three groups
(Figure 3A). Thereafter, plasma glucose level was
clamped at relatively constant level of 14-14.5 mmol/l
for 120 min. The glucose infusion rate (GIR), an index
of the maximum capacity of beta cell insulin secretion,
was significantly 34 percent lower in obese MSG rats
than in normal group (p <0.05). Fenofibrate treatment
significantly decreased GIR by 52.7% compared to con-
trol group (10.2 ± 2.4 vs. 21.6 ± 3.5 mg/kg/min, Figure
3B). The dual phase of insulin secretion was observed in
obese MSG rats and normal rats. The insulin level in
model group was higher at each time point than in nor-
mal group (p <0.01). However, the increase ratio of
plasma insulin at 5 min in obese MSG rats remained
54.7 percent lower than the normal group (p <0.01).
The insulin peak at 5 min, namely first secretion phase,
was almost absent after fenofibrate treatment compared
to control group (Figure 3C and 3D, p <0.05).
Fenofibrate increases MDA level and decreases ATPase
activity in pancreatic mitochondrion in obese MSG rats
Fenofibrate treatment caused a significant 49% increase
of MDA level in pancreatic mitochondrion compared to
Figure 2 Fenofibrate alleviates dyslipidemia in obese MSG rats. Fasting cholesterol, triglyceride and major lipoproteins levels were assayed
on 4th week. Nor, normal rats. Con, water treated obese MSG rats. Fen, fenofibrate treated obese MSG rats. Values represented means ± s.e.m.
(n = 10-12). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
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Figure 4A). Pancreatic mitochondrial total ATPase activ-
ity in MSG obese rats was 37.4 percent lower than nor-
mal rats, and fenofibrate group showed a decreased
activity of total ATPase by 15.5% than control group
(Nor, 8.2 ± 1.3; Con, 5.2 ± 0.9; Fen, 4.4 ± 0.4. p <0.05,
Figure 4B). Moreover, the activities of pancreatic mito-
chondrial Na
+-K
+-ATPase in fenofibrate-treated group
were lower than that in control group (Figure 4C).
Fenofibrate upregulates NF-B and iNOS expression in
the pancreas in obese MSG rats
To explore the molecular mechanism responsible for the
biochemical changes induced by fenofibrate treatment,
we examined mRNA level of several genes involved in
insulin secretory process in the pancreas. Quantitative
RT-PCR analysis showed that NF- kappaB and iNOS
mRNA levels in the pancreas were increased by 1.9 fold
and 1.6 fold in fenofibrate treated group compared to
control group, respectively (p <0.01, Figure 5A). Uncou-
pling-protein 2 (UCP2), a mitochondrial protein
involved in cellular oxidant defense and ATP generation,
was found to be upregulated by 1.5 fold in fenofibrate
treated group compared to control group (Figure 5B).
PPAR alpha mRNA level in the pancreas was downre-
gulated by 2.6 fold in obese MSG rats compared to nor-
mal group, but it was not significantly changed after
fenofibrate treatment (Figure 5B).
The Western blot results showed that protein levels of
iNOS, TNF alpha and NF- kappaB p65 domain were
significantly higher in the pancreas after fenofibrate
treatment (Figure 5C). Double immunolabeling of islets
from fenofibrate treated animals showed that most
iNOS immunoreactive cells also exhibited insulin immu-
noreactivity (Figure 6F). And the upregulation of iNOS
expression in an islet in fenofibrate group accounted for
50-60 percent of total primary beta cells as shown in 6F
section compared with that (30 percent upregulation) of
Figure 3 Fenofibrate affects insulin secretion in obese MSG rats. Pancreatic beta cell function was evaluated by hyperglycemic clamp. After
sampling (t = 0 min) for the assay of the basal blood glucose and insulin, animals received intravenously a glucose bolus followed by a
constant infusion of glucose to maintain plasma glucose level at 14 mmol/l. (A) Plasma glucose level, (B) Glucose infusion rates (GIR), (C) Plasma
insulin level, and (D) Insulin stimulation ratio. Nor, normal rats. Con, water treated obese MSG rats. Fen, fenofibrate treated obese MSG rats.
Values represented means ± s.e.m. (n = 6-8). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
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iNOS expression islets covered around 70 percent of all
analyzed islets in fenofibrate treated animals. These
results demonstrate that fenofibrate upregulates iNOS
expression in islet beta cells in obese MSG rats.
Discussion
PPAR alpha controls several metabolic pathways of lipid
and glucose metabolism. Fibrates as PPAR alpha ago-
nists are clinically used to treat dyslipidemia in obesity,
metabolic syndrome and type 2 diabetes individuals.
PPAR alpha is expressed in pancreatic islets, and its
agonist has been reported to improve pancreatic beta
cell function in insulin-resistant rodents [23]. However,
other studies showed that PPAR alpha agonists pro-
duced a decrease in glucose-stimulated insulin secretion
in beta cells. Thus it remains unclear whether long term
use of PPAR alpha agonist in pre-diabetic or diabetic
animal models is benefit to beta cell function or not,
although PPAR alpha has both direct and indirect effects
on the islet including the modulation of systemic insulin
sensitivity [24,25].
The initial objective of this study was to observe the
effect of PPAR alpha agonist on lipid metabolism as
well as insulin resistance in obese MSG rats. The effects
of fenofibrate on lipid levels at the dose of 100 mg per
day for 4 weeks were also assessed. Fenofibrate therapy
lowered triglycerides and LDL-C level as well as HDL-C
as shown in Figure 2D. These results showed some var-
iance to that from clinical data in humans. Many
researches have confirmed that in rodents fibrates may
decrease HDL-C as a result of both decreased expres-
sion of HDL apolipoproteins, apoA-I and apoA-II and
the metabolism enzymes such as hepatic lipase [26-28].
B u ti nh u m a n sf i b r a t e sh a v eap o s i t i v ee f f e c to nH D L
cholesterol as well as on apoA-I and apoA-II concentra-
tions. This different regulatory effects seems to be
caused by differences apoA-I gene promoter in the two
species [29,30].
We found that the fasting plasma insulin level showed
a notable reduction after fenofibrate treatment as shown
in Figure 1H. And we have also found the similar results
in the normal Wistar rats treated with fenofibrate for 4
weeks. It is well established that plasma insulin level is
decreased due to improved insulin sensitivity in tissues
(the liver and muscle, two major targets of insulin
action) in obesity and Type 2 diabetes. However, our
r e s u l t ss h o w e dt h a tf e n o f i b rate did not improve insulin
sensitivity in obese MSG rats. Thus we wondered how
plasma insulin level was decreased and speculated that
insulin secretion may be impaired in obese MSG rats
after fenofibrate treatment. To test our hypothesis, we
measured insulin secretion in vivo with the hyperglyce-
mic clamp which allowed for the quantitation of
Figure 4 Fenofibrate increases MDA level and decreases ATPase activity in pancreatic mitochondrion in obese MSG rats. (A) MDA level,
(B) Total ATPase Activity, (C) Na
+-K
+-ATPase activity and (D) Ca
2+-Mg
2+-ATPase activity. Nor, normal rats. Con, water treated obese MSG rats. Fen,
fenofibrate treated obese MSG rats. Values represented means ± s.e.m. (n = 5-6). *p < 0.05, ***p < 0.001 vs. control.
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hyperglycemic stimulus. The hyperglycemic clamp has
been demonstrated to be a reliable technique to evaluate
insulin secretory function. The results in Figure 3
demonstrated that fenofibrate treated obese MSG rats
exhibited impaired insulin release in response to glucose
stimulation. Taken together, these data suggest that
decreased plasma insulin level in fenofibrate treated
obese MSG rats is not an adaptive response to insulin
sensitivity, but is a direct consequence of reduced insu-
lin secretion in pancreatic beta cells.
W h i l et h em e c h a n i s mb yw h i c hf e n o f i b r a t ei m p a i r s
insulin secretion is not completely understood, numer-
ous studies have shown that the combined effects of
oxidative stress and increased inflammatory mediators
served to decrease insulin expression and interfere with
insulin biosynthesis in diabetes state [31]. The augmen-
ted reactive oxygen or nitrogen species (ROS/RNS)
generation may play an important role in the diminished
capability of beta cells. Interestingly, we noted that feno-
fibrate did not modulate circulating SOD concentration
in obese MSG rats. Conversely, plasma MDA and NO
levels (shown in Figure 1F and 1G) were dramatically
increased and MDA level in pancreatic mitochondrion
(shown in Figure 4A) of fenofibrate treatment group
was augmented. These results indicate that fenofibrate
promotes systemic inflammation and oxidative stress.
Furthermore, our results showed that total ATPase
and Na
+/K
+-ATPase were decreased in pancreatic mito-
chondrion in fenofibrate treatment group (shown in Fig-
ure 4B and 4C), suggesting that the aggravation of lipid
peroxidation may interfere with mitochondrial ion trans-
port. Uncoupling-protein 2 (UCP2) is a mitochondrial
protein located on the inner mitochondrial membrane.
In pancreatic beta cells, UCP2 has been proposed as a
negative regulator of glucose-stimulated insulin
Figure 5 Fenofibrate upregulates NF- kappaB and iNOS expression in the pancreas in obese MSG rats. Quantitative RT-PCR analysis of
pancreatic NF- kappaB and iNOS mRNA levels (A), UCP2 and PPAR alpha mRNA levels (B) in the three groups. A comparative threshold cycle (CT)
method was used for relative quantification of gene expression using b-actin for normalization. Measurements were carried out in triplicate for
each sample. (C) Western blot analysis of pancreatic NF- kappaB p65, iNOS and TNF alpha protein levels in three groups. Beta actin served as
loading control. Data represented the mean of at least three independent experiments ± s.e.m. *p < 0.05, ** p < 0.01 vs. control.
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level in the pancreas of fenofibrate treated obese MSG
rats, thus we speculate that reduced insulin secretion
after fenofibrate treatment may be induced by increased
formation of oxidative products in the pancreas.
It is well known that high-fat diets or obesity result in
the activation of NF- kappaB, leading to over-expression
of its target genes such as IL-6, iNOS, TNF alpha
[33,34]. The induction of iNOS and excess production
of NO have been recognized as a major contributor to
beta cell injury [35,36]. Our studies showed that plasma
NO level was elevated and iNOS immunostaining was
stronger in islet cells in fenofibrate treatment group.
These observations indicated that iNOS-derived NO
might serve as a physiological negative feedback
inhibitor of acute glucose-stimulated insulin release in
fenofibrate treated obese MSG rats [37,38]. Furthermore,
we found that fenofibrate increased NF- kappaB, TNF
alpha and iNOS expression both at mRNA and protein
levels in the pancreas, but had no obvious effects on
PPAR alpha expression. Collectively, our data strongly
suggested that upregulation of NF- kappaB and iNOS in
beta cells might contribute to the abnormal insulin
secretion in fenofibrate treated obese MSG rats.
Our observation is a preliminary study to evaluate the
effects of fenofibrate on beta cell function in animal
models. Even though it may have some extent difference
to the clinical patients, these findings could provide new
insight into the role of PPAR alpha agonists in the regu-
lation of beta cells function and call attention to the
Figure 6 Co-localization of iNOS and insulin in islets, fenofibrate upregulated iNOS expression in the islet beta cells.R e p r e s e n t a t i v e
confocal microscopy images showed the co-localization of iNOS and insulin in islets. Paraffin-embedded pancreas sections were double
immunostained by anti-insulin antibody and TRITC secondary (red) and anti-iNOS antibody and FITC secondary (green). A-C: insulin
immunoreactivity; D-F: iNOS immunoreactivity; G-I: co-localization of insulin-iNOS indicated by yellowish fluorescence. Scale bar: 30 μm. Nor,
normal rats. Con, water treated obese MSG rats. Fen, fenofibrate treated obese MSG rats.
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pre-diabetes and Type 2 diabetes patients.
Conclusions
In summary, fenofibrate impaired in vivo insulin secre-
tion stimulated by high glucose stimulation in obese
MSG rats. A more pronounced effect on the first phase
of insulin secretion suggests that ATP-dependent glu-
cose sensing is impaired, which may be due to increased
MDA level and decreased total ATPase activity in pan-
creatic mitochondrion. Up-regulated inflammatory med-
iators such as NF- kappaB and iNOS might contribute
to the fenofibrate induced impairments of islet insulin
secretion.
Acknowledgements
This work was supported by National Natural Science Foundation of China
(No. 30672494) and partly supported by the Key Project of the National
Eleventh-Five Year Research Program of China and National S&T Major
Special Project on Major New Drug Innovation (No. 2009ZX09303-003 and
No. 2009ZX09301-003-12-1). We thank Zi-liang Liu for technical help on
confocal scanning optical microscopy and related imaging. We also thank
Ph.D. Brian Nunnally for providing assistances in manuscript revision.
Authors’ contributions
SNL carried out studies including Real-time PCR, Western Blot and
immunofluorescence assays and all the data analyses. SNL and QL
performed the clamp test. LYL and SJS participated in the animal in vivo
experimental test and biochemical analysis. YH participated in the primers
sequence alignment. SNL and ZFS wrote the paper. ZFS designed the study
and in coordination with all others drafted the manuscript. All authors read
and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 July 2011 Accepted: 14 October 2011
Published: 14 October 2011
References
1. Jones PS, Savory R, Barratt P, Bell AR, Gray TJ, Jenkins NA, Gilbert DJ,
Copeland NG, Bell DR: Chromosomal localisation, inducibility,
tissuespecific expression and strain differences in three murine
peroxisome proliferator-activated receptor genes. Eur J Biochem 1995,
233:219-226.
2. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B,
Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B:
Peroxisome proliferator-activated receptor alpha activators improve
insulin sensitivity and reduce adiposity. J Biol Chem 2000,
275:16638-16642.
3. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW:
Peroxisome proliferator-activated receptor (PPAR)-alpha activation
lowers muscle lipids and improves insulin sensitivity in high fat-fed rats:
comparison with PPAR-gamma activation. Diabetes 2001, 50:411-417.
4. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG: Inverse
relationship between cytotoxicity of free fatty acids in pancreatic islet
cells and cellular triglyceride accumulation. Diabetes 2001, 50:1771-1777.
5. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR
alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006,
116:571-580.
6. Holness MJ, Smith ND, Greenwood GK, Sugden MC: Acute (24 h)
activation of peroxisome-proliferator-activated receptor (PPAR) alpha
reverses high-fat feeding induced insulin hypersecretion in vivo and in
perifused pancreatic islets. J Endocrinol 2003, 177:197-205.
7. Roduit R, Morin J, Massé F, Segall L, Roche E, Newgard CB, Assimacopoulos-
Jeannet F, Prentki M: Glucose downregulates the expression of the
peroxisome proliferator-activated receptor-alpha gene in the pancreatic
beta-cell. J Biol Chem 2000, 275:35799-35806.
8. Sugden MC, Greenwood GK, Smith ND, Holness MJ: Peroxisome
proliferator-activated receptor-alpha activation during pregnancy
attenuates glucose-stimulated insulin hypersecretion in vivo by
increasing insulin sensitivity, without impairing pregnancy-induced
increases in beta-cell glucose sensing and responsiveness. Endocrinology
2003, 144:146-153.
9. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H: Effects of
bezafibrate on beta-cell function of rat pancreatic islets. Eur J Pharmacol
2001, 426:201-206.
10. Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP,
Semenkovich CF: PPAR alpha suppresses insulin secretion and induces
UCP2 in insulinoma cells. J Lipid Res 2002, 43:936-943.
11. Bunyan J, Murrell EA, Shah PP: The induction of obesity in rodents by
means of monosodium glutamate. Br J Nutr 1976, 35:25-39.
12. Nagata M, Susuki W, Iisuka S, Takeda S, Aburada M, Miyamoto K: Type 2
diabetes mellitus in obese mouse model induced by monosodium
glutamate. Exp Anim 2006, 55:109-115.
13. Liu SN, Liu Q, Shen ZF: A preliminary study on the mechanism of
impaired beta cell function in monosodium glutamate obese rat with
insulin resistance. Acta Pharm Sin 2008, 43:1106-1111.
14. Tiedge M, Lortz S, Drinkgern J, Lenzen S: Relation between antioxidant
enzyme gene expression and antioxidative defense status of insulin-
producing cells. Diabetes 1997, 46:1733-1742.
15. Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y,
Fujitani Y, Kamada T, Kawamori R, Yamasaki Y: Glycation-dependent,
reactive oxygen species mediated suppression of the insulin gene
promoter activity in HIT cells. J Clin Invest 1997, 99:144-150.
16. Malaisse WJ, Boschero AC, Kawazu S, Hutton JC: The stimulus secretion
coupling of glucose-induced insulin release. XXVII. Effect of glucose on K
+ fluxes in isolated islets. Pflu"gers Arch 1978, 373:237-242.
17. Pecqueur C, Alves-Guerra MC, Gelly C, Levi-Meyrueis C, Couplan E, Collins S,
Ricquier D, Bouillaud F, Miroux B: Uncoupling protein 2, in vivo
distribution, induction upon oxidative stress, and evidence for
translational regulation. J Biol Chem 2001, 276:8705-8712.
18. Shalwitz RA, Beth TJ, MacLeod AM, Tucker SJ, Rolison GG: Use of 2H2O to
study labeling in plasma glucose and hepatic glycogen during a
hyperglycemic clamp. Am J Physiol 1994, 266:433-437.
19. Serradas P, Gangnerau MN, Giroix MH, Saulnier C, Portha B: Impaired
pancreatic beta cell function in the fetal GK rat. Impact of diabetic
inheritance. J Clin Invest 1998, 101:899-904.
20. Lowry OH, Rosebrough NJ, Farr ALl, Randall RJ: Protein measurement with
the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
21. Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G:
Potential of Light Cycler technology for quantification of minimal
residual disease in childhood acute lymphoblastic leukemia. Leukemia
2000, 14:316-323.
22. Viegas MS, Martins TC, Seco F, do Carmo A: An improved and cost-
effective methodology for the reduction of autofluorescence in direct
immunofluorescence studies on formalin-fixed paraffin-embedded
tissues. Eur J Histochem 2007, 51:59-66.
23. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M,
Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fiévet C, Staels B: Peroxisome
Proliferator-Activated Receptor alpha improves pancreatic adaptation to
insulin resistance in obese mice and reduces lipotoxicity in human
islets. Diabetes 2006, 55:1605-1613.
24. Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M:
Troglitazone prevents and reverses dyslipidemia, insulin secretory
defects, and histologic abnormalities in a rat model of naturally
occurring obese diabetes. Metabolism 2000, 49:1167-1175.
25. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H: Effects of
bezafibrate on beta-cell function of rat pancreatic islets. Eur J Pharmacol
2001, 426:201-206.
26. Krause BR, Barnett BC, Essenburg AD, Kieft KA, Auerbach BJ, Bousley R,
Stanfield R, Newton RS, Bisgaier CL: Opposite effects of bezafibrate and
gemfibrozil in both normal and hypertriglyceridemic rats. Atherosclerosis
1996, 127:91-101.
Liu et al. Journal of Translational Medicine 2011, 9:176
http://www.translational-medicine.com/content/9/1/176
Page 10 of 1127. Berthou L, Saladin R, Yaqoob P, Branellec D, Calder P, Fluchart JC,
Denèfle P, Auwerx J, Staels B: Regulation of rat liver apolipoprotein A-I,
apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by
fibrates and dietary fatty acids. Eur J Biochem 1995, 232:179-187.
28. Staels B, Van Tol A, Skretting G, Auwerx J: Lecithin: cholesterol
acyltransferase gene expression is regulated in a tissue-selective manner
by fibrates. J Lipid Res 1992, 33:727-735.
29. Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A,
Fruchart JC, Rubin E, Denèfle P, Staels B, Branellec D: Opposite regulation
of human versus mouse apolipoprotein A-I by fibrates in human
apolipoprotein A-I transgenic mice. J Clin Invest 1996, 97:2408-2416.
30. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B: Negative
regulation of the human apolipoprotein A-I promoter by fibrates can be
attenuated by the interaction of the peroxisome proliferator-activated
receptor with its response element. J Biol Chem 1994, 269:31012-31018.
31. Poitout V, Robertson RP: Glucolipotoxicity: fuel excess and beta-cell
dysfunction. Endocr Rev 2008, 29:351-366.
32. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-
Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB,
Lowell BB: Uncoupling protein-2 negatively regulates insulin secretion
and is a major link between obesity, beta cell dysfunction, and type 2
diabetes. Cell 2001, 105:745-755.
33. Zhou Z, Gengaro P, Wang W, Wang XQ, Li C, Faubel S, Rivard C, Schrier RW:
Role of NF-kappaB and PI 3-kinase/Akt in TNF-alpha-induced cytotoxicity
in microvascular endothelial cells. Am J Physiol Renal Physiol 2008,
295:932-941.
34. Dobashi K, Araki S, Kubo K, Kawagoe R, Yamamoto Y, Shirahata A:
Hydroxymethylglutaryl-CoA reductase inhibitor inhibits induction of
nitric oxide synthase in 3T3-L1 preadipocytes. Life Sci 2008, 82:85-90.
35. Størling J, Binzer J, Andersson AK, Züllig RA, Tonnesen M, Lehmann R,
Spinas GA, Sandler S, Billestrup N, Mandrup-Poulsen T: Nitric oxide
contributes to cytokine-induced apoptosis in pancreatic beta cells via
potentiation of JNK activity and inhibition of Akt. Diabetologia 2005,
48:2039-2050.
36. Konturek JW, Hengst K, Kulesza E, Gabryelewicz A, Konturek SJ,
Domschke W: Role of endogenous nitric oxide in the control of exocrine
and endocrine pancreatic secretion in humans. Gut 1997, 40:86-91.
37. Salehi A, Ekelund M, Lundquist I: Total parenteral nutrition-stimulated
activity of inducible nitric oxide synthase in rat pancreatic islets is
suppressed by glucagon-like peptide-1. Horm Metab Res 2003, 35:48-54.
38. Jimenez-Feltstrom J, Lundquist I, Salehi A: Glucose stimulates the
expression and activities of nitric oxide synthases in incubated rat islets:
an effect counteracted by GLP-1 through the cyclic AMP/PKA pathway.
Cell Tissue Res 2005, 319:221-230.
doi:10.1186/1479-5876-9-176
Cite this article as: Liu et al.: Long-term fenofibrate treatment impaired
glucose-stimulated insulin secretion and up-regulated pancreatic NF-
kappa B and iNOS expression in monosodium glutamate-induced
obese rats: Is that a latent disadvantage? Journal of Translational Medicine
2011 9:176.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. Journal of Translational Medicine 2011, 9:176
http://www.translational-medicine.com/content/9/1/176
Page 11 of 11